Clinical Trials Directory

Trials / Conditions / Multiple Sclerosis, Secondary Progressive

Multiple Sclerosis, Secondary Progressive

35 registered clinical trials studyying Multiple Sclerosis, Secondary Progressive8 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
NCT06900192
Stanford UniversityPhase 1
RecruitingEffects of Acute Intermittent Hypoxia on Neuroplasticity in MS
NCT06390930
Shirley Ryan AbilityLabN/A
RecruitingClinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
NCT06526364
University Hospital, Basel, Switzerland
CompletedPET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
NCT06683612
Contineum TherapeuticsPhase 1
Active Not RecruitingThe Synergistic Effects of AIH and FES in Persons With MS
NCT06413602
Shirley Ryan AbilityLabN/A
Active Not RecruitingKYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive
NCT06384976
Kyverna TherapeuticsPhase 2
RecruitingDevelopment of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
NCT06516458
Shirley Ryan AbilityLab
RecruitingIntermittent Hypoxia in Persons With Multiple Sclerosis
NCT06276634
Shirley Ryan AbilityLabN/A
RecruitingA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Prog
NCT06138132
Stanford UniversityPhase 1
CompletedThe Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis
NCT06436131
Cyprus University of TechnologyN/A
CompletedAn Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853
LAPIX Therapeutics Inc.
RecruitingCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
NCT05961644
Institute of Psychiatry and Neurology, WarsawPhase 2 / Phase 3
UnknownMUSCLE - Nordic Walking in MUltiple SCLErosis
NCT05385731
Leonardo A. Peyré-TartarugaN/A
UnknownExercise Effects in Multiple Sclerosis
NCT05496881
University of ReginaN/A
CompletedNovel Imaging Markers in SPMS
NCT05357833
University of UtahEARLY_Phase 1
Active Not RecruitingSafety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
NCT05168384
Abu Dhabi Stem Cells CenterPhase 1 / Phase 2
Active Not RecruitingNeuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
NCT05122559
Emmanuelle Waubant, MD PhDPhase 2
RecruitingMS-ResearchBiomarkerS
NCT05204459
Cedars-Sinai Medical Center
CompletedMotor Asymmetry in Progressive Multiple Sclerosis Patients
NCT04918225
Rennes University Hospital
UnknownHydroxychloroquine and Indapamide in SPMS
NCT05013463
University of CalgaryPhase 2
UnknownDiscontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
NCT04260711
Amsterdam UMC, location VUmcN/A
CompletedPhase II Clinical Trial of OCH-NCNP1
NCT04211740
National Center of Neurology and Psychiatry, JapanPhase 2
UnknownSensitivity of Motor Assessment in MS - a Prospective Cohort Study
NCT04993274
Friedemann Paul
CompletedCortical Lesions in Patients With Multiple Sclerosis
NCT03653585
Danish Research Centre for Magnetic Resonance
CompletedIntranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
NCT02988401
Johns Hopkins UniversityPhase 1 / Phase 2
CompletedOpen-label Study of Liothyronine in MS
NCT02506751
Johns Hopkins UniversityPhase 1
TerminatedBG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
NCT02430532
BiogenPhase 3
CompletedDomperidone in Secondary Progressive Multiple Sclerosis (SPMS)
NCT02308137
University of CalgaryPhase 2
UnknownEfficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
NCT02273635
Innobioscience SpAPhase 1 / Phase 2
CompletedSafety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
NCT01982942
MediciNovaPhase 2
CompletedImaging of Intracerebral Inflammation in MS
NCT02305264
Assistance Publique - Hôpitaux de ParisN/A
CompletedEfficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
NCT01433497
AB SciencePhase 3
CompletedBayer/Cognitive Assessments With Multiple Sclerosis Subjects
NCT00888277
University of Louisville
TerminatedEfficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
NCT00468611
BioMS Technology Corp.Phase 3
CompletedDose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
NCT00587691
Opexa Therapeutics, Inc.Phase 1 / Phase 2